TET1 and cancer: As expected, longer PFS, adjusted by age, sex, cancer type and TMB, of patients with TET1-MUT was observed (Fig. 3c, hazard ratio [HR] = 0.46 [95% CI, 0.25 to 0.82], adjusted P = 0.008).